Alaunos Therapeutics, Inc. reported earnings results for the second quarter ended June 30, 2023. For the second quarter, the company reported net loss was USD 8.77 million compared to USD 9.93 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.75 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.72 USD | +10.09% |
|
+15.74% | -32.11% |
06-10 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
05-15 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-32.11% | 10.47M | |
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023